Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group;Klinische bewertung potentieller einsatzbereiche von rekombinantem faktor VIIa bei internistischen und pädiatrischen erkrankungen: Empfehlungen einer expertensruppe

Medizinische Klinik

Volumn 102, Issue 1, 2007, Pages 70-81

  Dempfle, Carl Erik ^a   Gulba, Dietrich ^b,j   Kirchmaier, Carl M ^c   Klamroth, Robert ^d   Korte, Wolfgang ^e   Lorenz, Reinhard ^f   Peck Radosavljevic, Markus ^g   Veldman, Alex ^h   Zotz, Rainer B ⁱ  

^a Hämostaseologie Klinikum Mannheim gGmbH   (Germany)

^b Krankenhaus Düren gGmbH   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Childrens Hospital   (Germany)

^g UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY HOSPITAL GIESSEN   (Germany)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j Krankenhaus Duren gem GmbH   (Germany)

more..

Author keywords

Bleeding; Coagulation disorder; Hemostasis; Recombinant factor VIIa

Indexed keywords

ARGATROBAN; COUMARIN DERIVATIVE; DANAPAROID; DESULFATOHIRUDIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; MELAGATRAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD CLOTTING DISORDER; CHILDHOOD DISEASE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; GASTROENTEROLOGY; HUMAN; LOW DRUG DOSE; REVIEW; THROMBOCYTOPATHY; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

EID: 33846446675     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-007-1012-9     Document Type: Review

References (142)

1. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004;2:899-909.
2. Al Douri M, Shafi T, Al Khudairi D, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgeiy. Blood Coagul Fibrinolysis 2000;11:Suppl 1:S121-7.
3. Almeida AM, Khair K, Hann I, et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003;121:477-81.
4. Altistent C, Lozano M, Sol E, et al. Dental extraction using rFVIIa in a patient with severe factor V deficiency. Haemophilia 2000;6:408-12.
5. Ameri A, Stolte S. Correlation of activated clotting time (ACT) with rFVIIa infusion and clinical efficacy in a patient with Glanzmann thrombasthenia and platelet alloantibodies. Thromb Haemost 2002;87:1084.
6. Amitrano L, Guardascione MA, Brancaccio V, et al. Coagulation disorders in liver disease. Semin Liver Dis 2002;22:83-96.
7. Ancliff P, Liesner R, Khair K, et al. The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath. Blood Coagul Fibrinolysis 1999;10:447-8.
8. Basso IN, Keeling D. Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinolysis 2004;15:503-4.
9. Batorova A, Lazur J, Cupanik P, et al. Successful treatment of postoperative bleeding with continous infusion of recombinant factor VIIa in patient with severe factor XI deficiency and allergic reactions to plasma. Thromb Haemost 1999;82:A1955.
10. Bern MM, Sahud M, Zukov O, et al. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 2005;11:20-5.
11. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106:2550-4.
12. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124:653-8.
13. Billio A, Pescosta N, Rosanelli C, et al. Successful short-term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency [Letter]. Blood Coagul Fibrinolysis 1997;8:249-50.
14. Billon S, Le Niger C, Escoffre-Barbe M, et al. The use of recombinant factor VIIa (NovoSeven) in a patient with factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001;12:551-3.
15. Boggio L, Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol 2001;112:1074-5.
16. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003;38:Suppl 1:S54-68.
17. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123-30.
18. Bouwmeester FW, Jonkhoff AR, Verheijen RH, et al. Successful treatment of life-threatening post-partum hemorrhage with recombinant activated factor VII. Obstet Gynecol 2003;101:1174-6.
19. Brown JB, Emerick KM, Brown DL, et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003;37:268-72.
20. Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002;124:852-4.
21. Busani S, Marietta M, Pasetto A, et al. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 2005;93:381-2.
22. Carreno V, Messner M, Arrieta J, et al. The effect of recombinant factor VIIa (NovoSeven®) on haemorrhage following dental surgery in patients with liver cirrhosis - a randomised placebo controlled study. Thromb Haemost 2001;Suppl:P2612.
23. Chuansumrit A, Chantarojanasiri T, Isarangkura P, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000;11:Suppl 1:101-5.
24. Chuansumrit A, Nuntnarumit P, Okascharoen C, et al. The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics 2002;110:169-71.
25. Chuansumrit A, Visanuyothin N, Puapunwattana S, et al. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency. J Med Assoc Thai 2002;85:Suppl 4:S1059-64.
26. Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor FVIIa (NovoSeven®) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996;26:150-4.
27. Cobos E, Keung Y-K, Akhter S, et al. Use of recombinant factor VIIa for major elective surgery in a patient with factor VII deficiency, retroperitoneal fibrosis and hydronephrosis - a case report. Clin Appl Thromb Hemost 1999;3:33-5.
28. Danilos J, Goral A, Paluszkiewicz P, et al. Successful treatment with recombinant factor VIIa for intractable bleeding at pelvic surgery. Obstet Gynecol 2003; 15:1172-3.
29. De Fabritiis P, Dentamaro T, Picardi A, et al. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004;89:243-5.
30. De Franchis R, ed. Portal hypertension III: Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies. Oxford: Blackwell Science, 2001.
31. Del Pozo Pozo AI, Jimenez-Yuste V, Villar A, et al. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis 2002;13:551-3.
32. Deveras RAE, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-8.
33. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001;7:Suppl 1:16-22.
34. Divanon F, Hecquard C, Borel-Derlon A. Experience with use of recombinant activated factor VII. J Clin Pharm Ther 2002;27:133-8.
35. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003;15:184-8.
36. Egan JR, Lammi A, Schell DN, et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2004;30:682-5.
37. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med 2002;28:Suppl 2:S248-55.
38. Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998;9:741-8.
39. Eskandari N, Feldman N, Greenspoon JS. Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstet Gynecol 2002;99:935-7.
40. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clinic Proc 2004;79:1495-500.
41. Friederich PW, Levi M, Bauer KA, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001;103:2555-9.
42. Friederich PW, Wever PC, Briet E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001;66:292-4.
43. Galan AM, Tonda R, Pino M, et al. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003;43:885-92.
44. Gerlach R, Marquardt G, Wissing H, et al. Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve sate hemostasis. Case report. J Neurosurg 2002;96: 946-8.
45. Gerotziafas GT, Zervas C, Gavrielidis G, et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69:219-22.
46. Gielen-Wijffels SE, Van Mook WN, Van der Geest S, et al. Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation. Intensive Care Med 2004;30:1232-4.
47. Gostout CJ. Pharmacotherapy of acute non-variceal bleeding. Dig Dis 1998;16:263-5.
48. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003;14:117-20.
49. Grossmann RE, Geisen U, Schwender S, et al. Continuous infusion of recombinant factor VIIa (NovoSeven®) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000;83:633-4.
50. Halkos ME, Levy JH, Chen E, et al. Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. Ann Thorac Surg 2005;79:1303-6.
51. Hendriks HGD, van der Maaten JMAA, de Wolf J, et al. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant Factor VII. Anesth Analg 2001;93:287-9.
52. Heyman C von, Hotz H, Konertz W, et al. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002;16: 615-6.
53. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.
54. Holcomb JB, Neville HL, Fischer CF, et al. Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient. Curr Surg 2003;60:423-7.
55. Hu Q, Brady JO. Recombinant activated factor VII for treatment of enoxaparin-induced bleeding. Mayo Clin Proc 2004;79:827.
56. Huvers F, Slappendel R, Benraad B, et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005;63: 184-6.
57. Ingerslev J, Knudsen L, Hvid I, et al. Use of recombinant factor VIIa in factor-VII-deficient patients. Haemophilia 1997;3:215-8.
58. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 2000;46: Suppl 3-4):III1-15.
59. Jaschinski U, Ried M, Lichtwarck-Aschoff M, et al. Bleeding diathesis due to failed antagonism of heparin: successful treatment with recombinant factor VIIa. Anesth Analg 2004;99:1872.
60. Jeffers L, Chalasani N, Balart L, et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic fiver biopsy. Gastroenterology 2002;123:118-26.
61. Jimenez-Yuste V, Villar A, Morado M, et al. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia 2000;6:588-90.
62. Karadimov D, Binev K, Nachkov Y, et al. Use of activated recombinant factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol 2003;15:330-2.
63. Karkouti K, Beatti WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005;45:26-34.
64. Kastrup M, Heymann C von, Hotz H, et al. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg 2002;74:910-2.
65. Kessler CM. Antidotes to haemorrhage: recombinant factor VIIa. Best Pract Res Clin Haematol 2004;17:183-97.
66. Klamroth R, Gottsein S, Seibt F, et al. Control of haemostasis in patients with acquired factor X-deficiency due to systemic AL-amylodosis. Hämostaseologie 2004;21:A41.
67. Koster A, Merkle F, Hansen R, et al. Eliminiation of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 2000; 91:265-9.
68. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996;26:Suppl 1:159-64.
69. Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004;9:317-32.
70. Laffan MA, Tait RC, Blatny J, et al. Use of recombinant activated factor VII for bleeding in pancreatitis: a case series. Pancreas 2005;30:279-84.
71. Lawler P, White B, Pye S, et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002;8:145-8.
72. Lewis B, O'Leary M, Vinh T. Successful use of rVIIa (NovoSeven®) to reverse enoxaparin (Lovenox) overdose in an adult patient with intracranial bleeding. Presented at th ISTH Congress, Paris, July 6-12, 2001:P2633.
73. Lin J, Hanigan WC, Tarantino M, et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003;98:737-40.
74. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003;101:1864-70.
75. Lodge JPA, Jonas S, Jones RM, et al., on behalf of the rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplant 2005;11:973-9.
76. Lodge JPA, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection. Anesthesiology 2005;102:269-75.
77. Maimon M, Bernstein T, Kenet G. Recombinant factor VIIa for treatment of a child with severe factor VII deficiency and coarctation of the aorta. J Pediatr Hematol Oncol 2002;25:591.
78. Majumdar G, Phillips JK, Lavallee H, et al. Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa. Blood Coagul Fibrinolysis 1993;4:1035-7.
79. Malherbe S, Tsui BCH, Stobart K, et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004;100:443-5.
80. Mannucci PM, Federici AB. Management of inherited von Willebrand disease. Best Pract Res Clin Haematol 2001;14:455-62.
81. Mariani G, Testa MG, Di Paolantonio T, et al. Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999;77:131-6.
82. Mathijssen NCJ, Masereeuw R, Verbeek K, et al. Prophylaxis effect of recombinant factor VIIa in factor VII deficient patients. Br J Hematol 2004;125:494-9.
83. Matyskova M, Vorlova Z, Habart D, et al. Recombinant coagulation factor VIIa in the management of bleeding in patients with von Willebrand disease type 2A. Transfus Apher Sci 2004;31:75-7.
84. Mayer SA, Nikolai C, Brun MD, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
85. Meijer K, Peters F, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinolysis 2001;12:211-3.
86. Meijer K, Sieders E, Slooff MJ, et al. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII. Thromb Haemost 1998;80:204-5.
87. Michalska-Krzanowska G, Sajdak R, Stasiak-Pikula E. Effects of recombinant factor VIIa in haemorrhagic complications of urological operations. Acta Haematol 2003;109:158-60.
88. Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001;14:401-36.
89. Minnema MC, Ten Cate H, Hack E. The role of factor XI in coagulation: a matter of revision. Semin Thromb Hemost 1999;25:419-28.
90. Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001;114:174-6.
91. Muleo G, Santoro R, Iannaccaro P, et al. The use of recombinant activated factor VII in congenital and acquired factor VII deficiencies [Letter]. Blood Coagul Fibrinolysis 1998;9:389-90.
92. Naik VN, Mazer CD, Latter DA, et al. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anesth 2003;50:599-602.
93. Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003;82:257-8.
94. O'Connell NM. Factor XI deficiency. Semin Hematol 2004;41:Suppl 1:76-81.
95. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol 2002;22:672-4.
96. Pandit PB, O'Brien K, Asztalos E, et al. Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant. Arch Dis Child Fetal Neonatal Ed 1999;81:F40-4.
97. Panek G, Derlatka P, Bidzinski M, et al. Successful use of activated recombinant FVIIa in the management of intra abdominal haemorrhage after cytoreductive surgery for advanced carcinoma of the ovary - a case report. Nowotwory 2002;52:309-11.
98. Park P, Fewel ME, Garton HJ, et al. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003;53:34-9.
99. Pehlivanov B, Milchev N, Kroumov G. Factor VII deficiency and its treatment in delivery with recombinant factor VII. Eur J Obstet Gynecol Reprod Biol 2004;116:237-8.
100. Perry D. Review factor VII deficiency. Br J Haematol 2002;118:689-700.
101. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352.
102. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplant 2005;11:895-900.
103. Poon MC, Demers C, Jobin F, et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999;94:3951-3.
104. Poon MC, D'Oiron R, Depka M von, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004;2:1096-103.
105. Potapov EV, Pasic M, Bauer M, et al. Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg 2002;74:2182-3.
106. Price G, Kaplan J, Skowronski G. Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post-partum patient. Br J Anaesth 2004;93:298-300.
107. Quan DJ, Bass NM, Hirose R. The effect of recombinant factor VIIa and fresh frozen plasma on the INR in patients with acute and chronic liver failure. Hepatology 2003;38:806.abstract.
108. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, et al. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin Gastroenterol Hepatol 2004;2:78-84.
109. Sallah S, Husain A, Nguyen NP. Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2004;15:577-82.
110. Sanchis CJ, Andres Blasco CJ, Mena-Duran AV. Treatment of acute bleeding with recombinant factor VIIa in a patient with IgA deficit receiving anticoagulant therapy. Acta Haematol 2003;110:51-2.
111. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999;5:253-9.
112. Smaradottir A. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. Thromb Haemost 2004;92:666-7.
113. Sørensen B, Johansen P, Nielsen GL, et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14:469-77.
114. Stepinska J, Banaszewski M, Konopka A, et al. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost 2002;87:355-6.
115. Stratmann G, deSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 2004;98:1635-9.
116. Streif W, Borum AR, Paes B, et al. Influence of activated factor VII concentrates on thrombin generation in full-term and preterm neonates. Blood Coagul Fibrinolysis 2000;11:Suppl 1:S133-4.
117. Surudo T, Wojcicki M, Milkiewicz P, et al. Rapid correction of prothrombin time after low-dose recombinant factor VIIa in patients undergoing orthotopic liver transplantation. Transplant Proc 2003;35:2323-5.
118. Svartholm E, Annerhagen V, Lanne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa. Anesthesiology 2002;96:1528.
119. Takabe K, Holman PR, Herbst KD, et al. Successful perioperative management of factor X deficiency associated with primary amyloidosis. J Gastrointest Surg 2004;8:358-62.
120. Talkad A, Mathews M, Honings D, et al. Reversal of warfarin-induced anticoagulation with factor VIIa prior to rt-PA in acute stroke. Neurology 2005;64:1480-1.
121. Tanaka KA, Waly AA, Cooper WA, et al. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003;98:1513-5.
122. Tarantino MD, Aberle R. Recombinant factor VIIa (NovoSeven®) tor post-prostatectomy hemorrhage in a patient with type I von Willebrand disease. Am J Hematol 2001;68:62-3.
123. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
124. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996;75:981-2.
125. Tobias JD. Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology 2002;96:1522-5.
126. Udvardy M, Telek B, Mezey G, et al. Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer). Blood Coagul Fibrinolysis 2004;15:265-7.
127. Van Buuren HR, Wielenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci 2002;47:2134-6.
128. VanderKolk WE, Kurz P, Daniels J, et al. Liver hemorrhage during laparotomy in patients with necrotizing enterocolitis. J Pediatr Surg 1996;31:1063-6.
129. Veldman A, Fischer D, Voigt B, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002;28:1635-7.
130. Veldman A, Rettwitz W. Saftey profile of prophylactic rFVIIa treatment in preterm neonates during the first 72h of life. Crit Care Med 2003;31:A91.
131. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid pre-operative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002;8:CS98-100.
132. Waddington DP, McAuley FT, Hanley JP, et al. The use of recombinant factor VIIa in a Jehovah's Witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002;119:286-8.
133. Wahlgren CM, Swedenborg J. The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2003;26:221-2.
134. Wehbi MA, Obideen K, Martinez E, et al. Recombinant factor VIIa (rFVIIa) as a safe and effective therapeutic option for the correction of moderate to severe hepatic coagulopathy. Hepatology 2003;38:667.abstract.
135. Westrup D, Bassus S, Kirchmaier C, et al. Ultrastructure of a platelet clot from a thrombasthenia patient with no GPIIb/IIIa receptors and the influence of rFVIIa substitution. Platelets 2002;13: 487-91.
136. White B, O'Connor H, Smith OP. Successful use of recombinant VIIa (NovoSeven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency. Blood Coagul Fibrinolysis 2000;11:155-7.
137. Wolzt M, Levi M, Sarich TC, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004;91:1090-6.
138. Wong WY, Huang WC, Miller R, et al. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia 2000;6:50-4.
139. Wordliczek J, Serednicki W, Grabowska I, et al. A 43-year-old man was admitted to the hospital with the diagnosis of acute pancreatitis of 4 days' duration [Letter to the Editor]. Pancreas 2003;26:101-2.
140. Young G, Nugent DJ. Prevention of bleeding complications in neonates with liver failure undergoing surgery using recombinant factor VIIa. Hematology 2001;6:341-6.
141. Zietkiewicz M, Garlicki M, Domagala J et al. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a ventricular assist device. J Thorac Cardiovasc Surg 2002;123:384-5.
142. Zulfikar B, Kayran SM. Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis 2004; 15:261-3.